Italia markets open in 6 hours 6 minutes

Eli Lilly and Company (0Q1G.L)

LSE - LSE Prezzo differito. Valuta in CHF.
Aggiungi a watchlist
81,83-143,48 (-63,68%)
Alla chiusura: 12:51PM BST
Schermo intero
Chiusura precedente225,31
Aperto244,96
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno244,96 - 244,96
Intervallo di 52 settimane244,96 - 244,96
Volume435
Media VolumeN/D
Capitalizzazione744,227M
Beta (5 anni mensile)0,38
Rapporto PE (ttm)0,13
EPS (ttm)6,52
Prossima data utili01 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results

    Q4 2021 net loss was $(0.48) per basic and diluted share and adjusted non-GAAP net income* was $0.87 per basic and $0.85 per diluted shareFY 2021 net loss was $(0.66) per basic and diluted share and adjusted non-GAAP net income* was $2.64 per basic and $2.59 per diluted shareEarly trends1 indicate that Q1 2022 revenue is expected to be in the range of $120 million - $130 million and adjusted non-GAAP earnings per share* in the range of $3.80 - $4.10Commenced shipment of vasopressin, a generic al

  • GlobeNewswire

    ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022

    SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2022. “2021 was a year of substantial corporate and clinical accomplishments for ALX Oncology. We initiated numerous clinical trials, including two Phase 2 trials in head and neck squamous cell c

  • FX Empire

    Why Eli Lilly Stock Is Up By 8% Today

    The stock is trying to settle above the $270 level.